Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$5.34
-2.3%
$10.93
$4.20
$28.60
$3.73M1.46274,518 shs19,503 shs
Graphite One Inc. stock logo
GPH
Graphite One
C$0.71
C$0.85
C$0.64
C$1.14
C$114.35M1.380765109,221 shs213,301 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.43
+31.6%
$0.38
$0.25
$0.48
$36.86M1.08913,992 shs214,616 shs
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
$1.43
$0.51
$77.77
$30.72M1.681.37 million shs941,400 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
+4.00%+16.67%-45.51%-10.05%-25.41%
Graphite One Inc. stock logo
GPH
Graphite One
-1.39%-2.74%-30.39%-6.58%-5.33%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+0.95%+1.67%+15.76%+41.53%+21.19%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$5.34
-2.3%
$10.93
$4.20
$28.60
$3.73M1.46274,518 shs19,503 shs
Graphite One Inc. stock logo
GPH
Graphite One
C$0.71
C$0.85
C$0.64
C$1.14
C$114.35M1.380765109,221 shs213,301 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.43
+31.6%
$0.38
$0.25
$0.48
$36.86M1.08913,992 shs214,616 shs
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
$1.43
$0.51
$77.77
$30.72M1.681.37 million shs941,400 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
+4.00%+16.67%-45.51%-10.05%-25.41%
Graphite One Inc. stock logo
GPH
Graphite One
-1.39%-2.74%-30.39%-6.58%-5.33%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+0.95%+1.67%+15.76%+41.53%+21.19%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.00
Buy$24.00349.86% Upside
Graphite One Inc. stock logo
GPH
Graphite One
0.00
N/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88803.26% Upside
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORPH, GPH, IGC, and ARTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyHold
8/26/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
8/18/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
8/4/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $18.00
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$20.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AC$0.01 per share94.17C$0.44 per shareN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.33M29.36N/AN/A$0.08 per share5.36
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/A$2.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$19.05N/AN/AN/AN/A-497.68%-213.76%11/11/2025 (Estimated)
Graphite One Inc. stock logo
GPH
Graphite One
-C$4.90M-C$0.06N/AN/AN/A-10.96%-6.61%N/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
-$97.01MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ORPH, GPH, IGC, and ARTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.13-$5.61-$5.48-$5.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.39
0.39
Graphite One Inc. stock logo
GPH
Graphite One
0.02
1.09
0.33
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.14
1.80
N/A

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Graphite One Inc. stock logo
GPH
Graphite One
0.21%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
10.74%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5.80%
Graphite One Inc. stock logo
GPH
Graphite One
28.81%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
23.66%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5700,000663,000Not Optionable
Graphite One Inc. stock logo
GPH
Graphite One
20161.05 millionN/ANot Optionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
14135.31 millionN/ANot Optionable

Recent News About These Companies

Artiphon’s new Orba instrument can sample sounds live

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$5.34 -0.13 (-2.29%)
As of 12:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Graphite One stock logo

Graphite One CVE:GPH

C$0.71 0.00 (0.00%)
As of 12:10 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.43 +0.10 (+31.55%)
As of 12:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Orphazyme A/S stock logo

Orphazyme A/S NASDAQ:ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.